EQS-News: HAEMATO AG: Dividend of EUR 1.20
|
EQS-News: HAEMATO AG
/ Key word(s): Dividend
HAEMATO AG: Dividend of EUR 1.20
16.05.2023 / 17:40 CET/CEST
The issuer is solely responsible for the content of this announcement.
Dividend of EUR 1.20
Berlin, May 16, 2023 - At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to the Annual General Meeting taking place in presence on July 18th 2023.
About HAEMATO:
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceutical drugs (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.
.Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]
16.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
HAEMATO AG |
|
Lilienthalstraße 5c |
|
12529 Schönefeld |
|
Germany |
| Phone: |
+49 (0)30 897 30 86 70 |
| Fax: |
+49 (0)30 897 30 86 79 |
| E-mail: |
[email protected] |
| Internet: |
www.haemato.ag |
| ISIN: |
DE000A289VV1 |
| WKN: |
A289VV |
| Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1634693 |
| |
| End of News |
EQS News Service |
1634693 16.05.2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
289,86 |
274,12 |
197,84 |
238,33 |
285,04 |
248,14 |
282,00 |
| EBITDA1,2 |
11,27 |
9,96 |
1,90 |
3,31 |
12,64 |
9,66 |
12,40 |
| EBITDA-Marge3 |
3,89 |
3,63 |
0,96 |
1,39 |
4,43 |
3,89 |
|
| EBIT1,4 |
9,42 |
8,50 |
-18,68 |
1,63 |
11,16 |
8,30 |
11,40 |
| EBIT-Marge5 |
3,25 |
3,10 |
-9,44 |
0,68 |
3,92 |
3,35 |
4,04 |
| Jahresüberschuss1 |
6,98 |
6,28 |
-1,17 |
-4,83 |
6,53 |
8,19 |
6,90 |
| Netto-Marge6 |
2,41 |
2,29 |
-0,59 |
-2,03 |
2,29 |
3,30 |
2,45 |
| Cashflow1,7 |
-8,35 |
0,56 |
-2,76 |
14,67 |
14,05 |
19,73 |
0,00 |
| Ergebnis je Aktie8 |
3,20 |
2,70 |
-0,50 |
-1,02 |
1,35 |
1,57 |
1,34 |
| Dividende8 |
3,00 |
1,00 |
0,00 |
0,00 |
1,10 |
1,20 |
3,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Harry Haseloff
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Haemato |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| A289VV |
16,800 |
- |
87,85 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 10,50 |
15,55 |
0,68 |
8,45 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 0,62 |
4,45 |
0,35 |
6,91 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 1,20 |
0,70 |
4,17 |
18.07.2023 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 31.05.2023 |
31.08.2023 |
16.11.2023 |
17.05.2023 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -12,05% |
-22,64% |
-36,84% |
-6,15% |
|
|
HAEMATO AG DE000A289VV1